Quantum Genesis AI Corp. has issued a statement regarding the Caveat Emptor designation placed on the company's securities by OTC Markets Group, Inc. on February 12, 2026. The designation, which indicates potential risks for investors, was applied due to what OTC Markets described as a "public interest concern." Since the designation, the company has made several attempts to communicate with OTC Markets to better understand the basis for the designation and determine necessary steps to address it. The company has requested additional clarification and intends to continue cooperating with OTC Markets. OTC Markets recently informed Quantum Genesis AI that it may formally request a review of the Caveat Emptor designation beginning March 13, 2026. The company plans to engage with OTC Markets at the earliest available opportunity to initiate that review process. For more information, investors can visit the company's website at https://www.qgaicorp.com and its profile at https://www.otcmarkets.com/stock/QGAI.
Naveen Kulkarni, Chief Executive Officer of Quantum Genesis AI Corp., stated that the company takes the matter seriously and is committed to working constructively with OTC Markets. "Our objective is to obtain clarity regarding the matter and to take any appropriate steps necessary as we move through the review process," Kulkarni said. The company remains committed to maintaining transparency with its shareholders and the broader investment community and intends to provide updates as additional information becomes available. The Caveat Emptor designation highlights regulatory scrutiny that can affect investor confidence and market perception. For companies trading on OTC markets, such designations can impact stock liquidity and valuation, making resolution through formal review processes critical. Quantum Genesis AI's response underscores the importance of corporate transparency and regulatory compliance in maintaining market integrity. The outcome of the review process could have implications for the company's ability to attract investment and operate in regulated financial markets. This situation matters because it illustrates how regulatory actions can directly influence a company's market standing and investor trust, with potential consequences for financial stability and growth prospects. The designation serves as a reminder of the risks associated with OTC-traded securities and the need for diligent oversight. Quantum Genesis AI's proactive approach in seeking clarification and engaging in the review process demonstrates a commitment to addressing regulatory concerns, which is essential for preserving shareholder value and market credibility. The resolution of this matter will be closely watched by investors and regulators alike, as it may set a precedent for how similar cases are handled in the future, impacting the broader landscape of OTC trading and corporate governance standards.
